Sign Up
S 4302 United States Senate · 117th Congress

Biologics Market Transparency Act of 2022

Summary
Biologics Market Transparency Act of 2022 This bill requires biologics manufacturers to notify the Food and Drug Administration in advance of withdrawing a product from sale.
Issues: ✓ HealthcareSupports HealthcareRequires FDA notification for biologics withdrawal, preventing sudden shortages and ensuring patient access to critical treatments.85% confidence
Bill status in committee 1 of 4 stages cleared
Introduction
May 2022
Committee Review
Floor Vote
President
Introduced May 25, 2022 Last action May 25, 2022
Floor votes

How they voted

No floor votes recorded yet.
Full legislative history

Actions timeline

Total actions
2
Key actions
0
Committee
1
May 25, 2022
Committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)
upper
May 25, 2022
Introduced
Introduced in Senate
upper
1 primary · 3 co-sponsors

Sponsors

Role
Legislator
Party
State
District
P
Photo of Tim Kaine
Tim Kaine
DDemocratic
VA
n/a
Co
Photo of Bill Cassidy
Bill Cassidy
RRepublican
LA
n/a
Co
Photo of Margaret Wood Hassan
Margaret Wood Hassan
DDemocratic
NH
n/a
Co
Photo of Roger Marshall
Roger Marshall
RRepublican
KS
n/a